# mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)

Source: https://nuclide.cc/terms/mcrpc-mhspc/  
Nuclide record `mcrpc-mhspc` (Term). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Prostate cancer starts out fed by testosterone (hormone-sensitive) and shrinks when it is removed. When it learns to grow despite castrate testosterone levels it is called castration-resistant, a later and more dangerous stage with its own treatments.

## Summary

Metastatic hormone-sensitive disease (mHSPC) is treated with androgen deprivation plus an ARPI (abiraterone, enzalutamide, apalutamide, darolutamide) and sometimes docetaxel (STAMPEDE, LATITUDE, ARASENS), which delays castration resistance by years. Castration-resistant disease (CRPC), defined by PSA or radiographic progression with testosterone <50 ng/dL, arises through androgen receptor amplification, mutations, splice variants (AR-V7) and intratumoural androgen synthesis; it is treated with ARPI switch, docetaxel and cabazitaxel, PARP inhibitors for HRR mutations, 177Lu-PSMA-617 (VISION, PSMAfore) and radium-223. Non-metastatic CRPC (rising PSA, clear scans) has its own approvals. Radiographic PFS (rPFS) is the usual endpoint.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: castration-resistant; castration resistant; castrate-resistant; mCRPC; nmCRPC; CRPC; castration-sensitive; castration sensitive; hormone-sensitive; hormone sensitive; mHSPC; mCSPC; HSPC; hormone-naive; hormone-refractory; biochemical recurrence; PSA recurrence; rising PSA; PSA progression; rPFS

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer#Castration-resistant_prostate_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer#Castration-resistant_prostate_cancer

## Connected records

- terms: [Androgen receptor pathway inhibitor (ARPI)](https://nuclide.cc/terms/arpi/)
- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/), [Radium-223](https://nuclide.cc/isotopes/ra-223/)
- indications: [Non-metastatic castration-resistant prostate cancer](https://nuclide.cc/indications/prostate-nmcrpc/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- drugs: [Abiraterone acetate](https://nuclide.cc/drugs/abiraterone/), [Enzalutamide](https://nuclide.cc/drugs/enzalutamide/)
- trials: [PSMAfore](https://nuclide.cc/trials/psmafore/), [STAMPEDE](https://nuclide.cc/trials/stampede/), [VISION](https://nuclide.cc/trials/vision/)
- fronts: [Radioligand therapy](https://nuclide.cc/fronts/f-radioligand-therapy/)

---
JSON: https://nuclide.cc/api/v1/entities/mcrpc-mhspc.json